Compare BVFL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BVFL | MDXH |
|---|---|---|
| Founded | 1873 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6M | 149.0M |
| IPO Year | 2023 | 2021 |
| Metric | BVFL | MDXH |
|---|---|---|
| Price | $19.40 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 13.2K | ★ 186.6K |
| Earning Date | 01-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.19 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $13.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.65 | $1.40 |
| 52 Week High | $19.88 | $5.33 |
| Indicator | BVFL | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 19.34 |
| Support Level | $18.22 | $1.90 |
| Resistance Level | $19.81 | $2.30 |
| Average True Range (ATR) | 0.49 | 0.23 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 92.89 | 9.02 |
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.